Axcan Pharma 2Q Net 7c/Share Vs Loss 3c
Dow Jones Newswires
Axcan Pharma Inc. - Mont Saint-Hilaire, Que.
2nd Quar March 31:
2001 2000
Revenues $24,636,000 $15,607,000
Inc cont op 2,492,000 (754,000)
Inc dis op .... 92,000
Net income 2,492,000 (662,000)
Avg shares 34,539,080 26,264,754
Shr earns (basic)
Inc cont op .07 (.03)
Inc dis op .... ....
Net income .07 (.03)
6 months:
Revenues 49,017,000 40,885,000
Inc cont op 4,313,000 1,103,000
Inc dis op .... 267,000
Net income 4,313,000 1,370,000
Avg shares 34,529,931 22,505,112
Shr earns (basic)
Inc cont op .12 .05
Inc dis op .... .01
Net income .12 .06
Figures in parentheses are losses.
A First Call/Thomson Financial survey estimated first-quarter earnings at 6 cents a share.
The company said it is encouraged by its performance in the first half and is confident it will meet its objectives for the year.
Research and development expenses were C$1.5 million in its latest quarter, up from C$1.3 million a year earlier. Six month R&D expenses were C$3.5 million versus C$2.3 million.
Axcan Pharma Inc. (AXCA) is a specialty pharmaceutical company.
Company Web Site: axcan.com |
